ArticleBMC cancer2023

MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.

Jinhui Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.